Trial Profile
A drug drug interaction study between rosiglitazone and SCY-078
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 May 2018
Price :
$35
*
At a glance
- Drugs Ibrexafungerp (Primary) ; Rosiglitazone (Primary)
- Indications Aspergillosis; Candidiasis; Vulvovaginal candidiasis
- Focus Pharmacokinetics
- 10 May 2018 Results published in the Journal of Clinical Pharmacology
- 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
- 12 Apr 2017 According to an SCYNEXIS media release, data from this study will be presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).